Search Results

touchONCOLOGY coverage of data presented at European Society of Medical Oncology (ESMO) 2024 Annual Congress The LEAP-012 trial is a phase III, randomized, double-blind study that evaluated the efficacy and safety of combining lenvatinib and pembrolizumab with transarterial chemoembolization (TACE) compared to placebo plus TACE in patients with intermediate-stage hepatocellular carcinoma (HCC). The study found […]

Hepatocellular carcinoma (HCC) is the seventh most frequently occurring cancer in the world and the second most common cause of cancer mortality.1 The incidence of HCC has been growing rapidly, with a 75% increase in newly diagnosed cases from 1990 to 2015.2 Approximately 90% of HCC cases are associated with an underlying aetiology, most frequently chronic viral […]

The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. Across GI tumour types, enhanced efficacy has been seen when these agents are used in […]

The antitumor activity of immune checkpoint inhibotors in various solid and haematologic malignancies has substantially increased immunotherapy implications for cancer. Once only a niche treatment for selected cancers (renal cancer and melanoma), now cancer immunotherapy has become an important option for many patients, even moving into the first-line systemic treatment setting for melanoma, non-small cell […]

touchONCOLOGY joins Professor Jean-Luc Van Laethem (Erasme University Hospital, Brussels, Belgium), principle investigator of the KEYNOTE-224 study, to discuss the updated results for pembrolizumab monotherapy as first-line therapy for advanced hepatocellular carcinoma. Questions 1. What were the objectives of the KEYNOTE-224 study? (00:38-01:33) 2. What have previous study findings taught us about the clinical utility […]